Celgene's Partnered Pipeline Delivers Successes And Setbacks

21 Nov 2017

Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.

Business partners hands on top of each other symbolizing companionship — Celgene's pipeline was built through many deals

Celgene Corp.'s aggressive deal-making strategy could pay off in a big way over the next several years, bringing in billions of dollars in annual sales from new drugs to diversify revenue beyond its multiple myeloma blockbuster Revlimid (lenalidomide) and the hematology/oncology franchise that dominates the company's commercial portfolio.

The deal-making strategy has been successful in filling Celgene's pipeline with several high-profile assets at a time when its large biotech and big pharma peers also are putting more emphasis...

Coming soon…

More exclusive Scrip 100 features and the full Scrip 100 2018 review

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

03 Jun 2025

• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

03 Jun 2025

• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

02 Jun 2025

• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

02 Jun 2025

• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

02 Jun 2025

• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.